Ondansetron

Primary Uses

Ondansetron is primarily prescribed to help manage and prevent nausea and vomiting in specific medical situations. It is commonly used for:

• Cancer Chemotherapy: It is used to prevent nausea and vomiting associated with cancer drug treatments that are known to cause these side effects.
• Radiation Therapy: It helps prevent nausea and vomiting in patients receiving radiation treatments, particularly those involving the abdomen or the entire body.
• Surgery: It is used to prevent nausea and vomiting that may occur after a patient undergoes a surgical procedure.

This medication belongs to a class of drugs called serotonin 5-HT3 receptor antagonists. It works by blocking serotonin, a natural substance in the body that can trigger the vomiting reflex.

Typical Administration

Ondansetron is often used as a preventive measure, meaning it is typically taken before a treatment (like chemotherapy or surgery) begins. Depending on the situation and the patient's needs, it may be administered in several ways:

• Standard oral tablets or an oral liquid solution.
• Orally disintegrating tablets that dissolve quickly on the tongue without the need for water.
• An injection, which is usually administered by a healthcare professional in a hospital or clinic setting.

Mechanism of Action

Ondansetron belongs to a class of medications called serotonin 5-HT3 receptor antagonists. It works by blocking the action of serotonin, a natural substance in the body that can cause nausea and vomiting.

During certain medical events, such as chemotherapy, radiation therapy, or surgery, the body may release an increased amount of serotonin. This chemical travels to specific receptors on nerves in the digestive system and the brain. When serotonin attaches to these receptors, it sends signals to the brain's vomiting center.

Ondansetron prevents this process by:

• Binding to 5-HT3 receptors in the small intestine.
• Blocking receptors in the area of the brain that controls the vomiting reflex.

By preventing serotonin from sending these signals, the medication helps reduce the urge to vomit and the sensation of nausea.

Common Side Effects

The most frequently reported side effects of ondansetron include:

• Headache
• Constipation
• Diarrhea
• Dizziness
• Drowsiness or tiredness
• Fever

Serious Side Effects

Contact a healthcare provider immediately or seek emergency medical attention if you experience any of the following serious symptoms:

• Signs of an allergic reaction, such as hives, rash, itching, or swelling of the face, lips, tongue, or throat
• Difficulty breathing or swallowing
• Chest pain or shortness of breath
• Fast, pounding, or irregular heartbeat
• Fainting or severe dizziness
• Vision changes, such as blurred vision or temporary vision loss
• Muscle stiffness, spasms, or loss of coordination
• Agitation, confusion, or hallucinations

Ondansetron may contribute to a rare but life-threatening condition called serotonin syndrome, particularly when used with other medications that affect serotonin levels. Symptoms can include shivering, heavy sweating, high fever, and severe diarrhea.

Heart Rhythm Changes

Ondansetron may cause changes in the electrical activity of the heart, known as QT interval prolongation. This can lead to a serious and potentially fatal heart rhythm called Torsade de Pointes. The risk is higher for individuals with certain conditions, such as:

• Congestive heart failure or slow heart rate (bradyarrhythmias).
• Low levels of potassium or magnesium in the blood.
• A personal or family history of long QT syndrome.

Serotonin Syndrome

A potentially life-threatening condition called serotonin syndrome can occur, especially when ondansetron is used with other drugs that affect serotonin levels, such as antidepressants (SSRIs, SNRIs, or MAOIs). Symptoms may include agitation, hallucinations, rapid heartbeat, dizziness, muscle tremors, or seizures.

Drug Interactions

Ondansetron should not be taken with apomorphine, as the combination can cause a severe drop in blood pressure and loss of consciousness.

Allergic Reactions

Severe allergic reactions, including anaphylaxis, have been reported. People who have had an allergic reaction to other selective 5-HT3 receptor antagonists (such as granisetron or palonosetron) may also be sensitive to ondansetron.

Other Precautions

Ondansetron may mask signs of a bowel obstruction or gastric distension following abdominal surgery. Additionally, orally disintegrating tablets may contain phenylalanine, which is a concern for individuals with phenylketonuria (PKU).

Pregnancy

The use of ondansetron during pregnancy is a subject of ongoing medical research. Some studies have suggested a potential, though small, increase in the risk of certain birth defects, such as heart problems or a cleft palate, particularly when used during the first trimester. However, other studies have not found a clear link between the medication and these issues.

Due to these uncertainties, healthcare providers generally recommend using ondansetron only when the benefits of controlling severe nausea and vomiting clearly outweigh the potential risks. It is important to discuss all available treatment options with a doctor if you are pregnant or planning to become pregnant.

Breastfeeding

It is not yet known if ondansetron passes into human breast milk or how it might affect a nursing infant. Because many medications can be transferred through breast milk, caution is advised. Individuals who are breastfeeding should consult their healthcare provider before using this medication to determine the safest course of action for both the parent and the child.

Oral Forms

Ondansetron is commonly taken by mouth in the following formats:

• Tablets: Standard tablets that are swallowed with water.
• Orally Disintegrating Tablets: Tablets designed to dissolve quickly on the tongue without the need to swallow water.
• Oral Solution: A liquid form of the medication.
• Oral Soluble Film: A thin strip that is placed on the tongue to dissolve.

Injectable Forms

Ondansetron is also available as a solution for injection. This form is typically administered by a healthcare professional in a clinical setting. It may be given in the following ways:

• Intravenous Injection: Delivered directly into a vein.
• Intramuscular Injection: Delivered into a muscle.

FDA Approval and Indications

Ondansetron was first approved by the U.S. Food and Drug Administration (FDA) in 1991. It is classified as a serotonin 5-HT3 receptor antagonist. The medication is currently approved for the prevention of nausea and vomiting in the following clinical situations:

• Initial and repeat courses of emetogenic cancer chemotherapy.
• Total body irradiation or localized abdominal radiation therapy.
• Postoperative recovery following surgical procedures.

Safety Communications and Labeling Changes

The FDA has issued safety communications regarding the risk of QT interval prolongation, which is a heart rhythm change that can lead to a serious and potentially fatal condition known as Torsade de Pointes. Based on clinical data, the FDA determined that the 32 mg single intravenous dose of ondansetron could significantly prolong the QT interval. Consequently, this specific dose was removed from the market and the drug labeling was updated to reflect that no single intravenous dose should exceed 16 mg.

Regulatory updates also advise caution and potential ECG monitoring for patients with electrolyte imbalances (such as low potassium or magnesium), congestive heart failure, or those taking other medications that may cause heart rhythm changes. Patients with congenital long QT syndrome are advised to avoid the use of ondansetron.

Regulatory Status

Ondansetron is available only by prescription. It is not currently subject to a Risk Evaluation and Mitigation Strategy (REMS) program and does not carry a boxed warning. It is available in several formulations, including oral tablets, orally disintegrating tablets (ODT), oral solutions, and injectable forms for intravenous or intramuscular use.